Quarterly report [Sections 13 or 15(d)]

REVENUES

v3.25.2
REVENUES
 6 Months Ended
Jun. 30, 2025
Revenue from Contract with Customer [Abstract]  
REVENUES

NOTE 10 – REVENUES

Disaggregation of Net Revenues

The Company’s net product revenues are summarized below: 

         
   

Three months ended 

June 30, 
    2025   2024
Zembrace Symtouch   $ 1,570   $ 1,727
Tosymra     428     481
Total product revenues   $ 1,998   $ 2,208

         
   

Six months ended 

June 30, 
    2025   2024
Zembrace Symtouch   $ 3,596   $ 3,574
Tosymra     831     1,116
Total product revenues   $ 4,427   $ 4,690

Gross-to-Net Sales Accruals

We record gross-to-net sales accruals for chargebacks, rebates, sales and other discounts, and product returns, which are all customary to the pharmaceutical industry.

Our provision for gross-to-net allowances was $5.8 million at June 30, 2025, $0.5 million of which was recorded as a reduction to accounts receivable and $5.3 million recorded as a component of accrued expenses. Our provision for gross-to-net allowances was $4.3 million at June 30, 2024, $0.6 million of which was recorded as a reduction to accounts receivable and $3.7 million recorded as a component of accrued expenses.